Loading…
Loading…
Sentiment · FY2026 Q3
| Analyst | Firm | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| Matt Larew | William Blair | 14 | 14% |
| Puneet Souda | Leerink Partners | 14 | 21% |
| Dan Leonard | UBS | 12 | 8% |
| Patrick Donnelly | Citigroup | 11 | 0% |
| Dan Arias | Stifel | 9 | 11% |
| Dan Markowitz | Evercore ISI | 7 | 14% |
| Sung Nam | Scotiabank | 6 | 0% |
| Kyle Boucher | TD Cowen | 6 | 0% |
| Mac Etoch | Stephens | 5 | 0% |
| Catherine Schulte | Robert W. Baird | 4 | 0% |
| Firm | Analysts | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| Leerink Partners | 1 | 14 | 21% |
| William Blair | 1 | 14 | 14% |
| UBS | 1 | 12 | 8% |
| Citigroup | 1 |
| 11 |
| 0% |
| Stifel | 1 | 9 | 11% |
| Evercore ISI | 1 | 7 | 14% |
| Stephens | 2 | 7 | 0% |
| TD Cowen | 1 | 6 | 0% |
Bio-Techne posted a 2% organic revenue decline to $311.4 million as cell therapy Fast Track timing and an OEM order shift created a combined 400 basis point headwind, masking 2% underlying growth. Emerging biotech surprised to the downside with a high single digit decline as early-stage funding lagged the headline recovery concentrated in late-stage programs. Bright spots included COMET spatial biology surging over 65% with a record backlog, GMP reagents growing nearly 50% ex-Fast Track customers, and US academic returning to growth for the first time. Management guided Q4 approximately flat and expressed confidence in mid-single-digit fiscal 2027 growth as biotech funding flows through and company-specific headwinds roll off.
Demand | Revenue Growth | Guidance Reliability | Macroeconomic | Margin | Product Launch | Cost Pressure | M&A | |
|---|---|---|---|---|---|---|---|---|
| 2025Q1 | 8 | 6 | 1 | 2 | 1 | 5 | 1 | 1 |
| 2025Q2 | 7 | 6 | 1 | 3 | 3 | 1 | 1 | 2 |
| 2025Q3 | 6 | 5 | 3 | 2 | 2 | 2 | 1 | |
| 2025Q4 | 8 | 5 | 5 | 5 | 3 | 2 | 2 | |
| 2026Q1 | 9 | 10 | 4 | 1 | 3 | 1 | 1 | |
| 2026Q2 | 7 | 4 | 2 | 2 | 3 | 2 | 3 | 1 |
| 2026Q3 | 7 | 6 | 3 | 3 | 1 |
| '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | '26Q2 | '26Q3 | |
|---|---|---|---|---|---|---|---|
| Demand | 8 | 7 | 6 | 8 | 9 | 7 | 7 |
| Revenue Growth | 6 | 6 | 5 | 5 | 10 | 4 | 6 |
| Guidance Reliability | 1 | 1 | 3 | 5 | 4 | 2 | 3 |
| Macroeconomic | 2 | 3 | 2 | 5 | 1 | 2 | 3 |
| Margin | 1 | 3 | 2 | 3 | 3 | 3 | |
| Product Launch | 5 | 1 | 2 | 2 | 1 | ||
| Cost Pressure | 1 | 1 | 2 | 1 | 3 | ||
| M&A | 1 | 2 | 1 | 2 | 1 | 1 |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
TECH Bio-Techne | 4 | -1.5% | |
| ALNY Alnylam Pharmaceuticals | 9 | +96.4% | |
| INCY Incyte | 9 | +20.9% | |
| INSM Insmed Incorporated | 8 | +229.6% | |
| MRNA Moderna | 8 | +263.6% | |
| REGN Regeneron Pharmaceuticals | 7 | +19.0% | |
| VRTX Vertex Pharmaceuticals | 6 | +7.8% |